Orion ORNBV.HE
Orion is a Finnish pharmaceutical company that develops, manufactures, and markets innovative and generic medicines. Orion combines exceptional growth (revenue +25.2%, earnings +69.5%) with impeccable financial health (net cash, ROE 53.65%), although its valuation is no longer cheap (P/E 20.13) and free cash flow is weak (33.84% conversion).
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Orion is a Finnish pharmaceutical company that develops, manufactures, and markets innovative and generic medicines. Orion combines exceptional growth (revenue +25.2%, earnings +69.5%) with impeccable financial health (net cash, ROE 53.65%), although its valuation is no longer cheap (P/E 20.13) and free cash flow is weak (33.84% conversion).
Score by category
| Category | Score |
|---|---|
| Financial health | 8.7 |
| Quality / Moat | 8.4 |
| Valuation | 4.5 |
| Growth | 9.1 |
| Dividend | 6.6 |
| Momentum | 6.4 |
| Risk & Context | 9.1 |
OVERALL SCORE: 7.6/10
Context and risks
No material geopolitical or regulatory exposure specific to Orion beyond the standard risk of the Finnish pharmaceutical sector.
News considered in the analysis
- Orion Oyj Hippo Pathway Data Adds New Dimension To Oncology Story — Los datos del ensayo Hippo refuerzan la cartera de oncología, un motor de crecimiento clave para Orion.
- Orion Oyj (HLSE:ORNBV) Has Investors Asking Questions — Titular genérico de análisis sin información nueva concreta.
- Orion Oyj (ORINF) Q1 2026 Earnings Call Highlights: Robust Growth and Strategic Outlook — Los resultados del primer trimestre ya son públicos y están reflejados en el precio; el crecimiento de ingresos del 25.2% ya se conoce.
- Is Orion Oyj (HLSE:ORNBV) Still Attractive After Strong Multi‑Year Share Price Gains? — Artículo de análisis genérico sin información nueva.
- Assessing Orion Oyj’s Valuation After Recent Share Price Strength And Long Term Returns — Análisis de valoración sin información nueva concreta.
Verdict: Hold: strong growth and quality justify the premium, but the margin of safety is limited at these prices.
Main risk: Weak free cash flow conversion (33.84%) may indicate that accounting growth is not translating into cash, a risk to dividend sustainability in the long term.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →